Clinical Trial Detail

NCT ID NCT02533115
Title EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML
Recruitment Approved for marketing
Gender both
Phase Expanded access
Variant Requirements No
Sponsors Celator Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

CPX-351

Age Groups: senior

No variant requirements are available.